These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9922630)

  • 21. Perseverance.
    Prescrire Int; 2011 Feb; 20(113):54. PubMed ID: 21488600
    [No Abstract]   [Full Text] [Related]  

  • 22. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
    Abraham J; Lewis G
    Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Licensing failure in the European decentralised procedure.
    Langedijk J; Ebbers HC; Mantel-Teeuwisse AK; Kruger-Peters AG; Leufkens HG
    Eur J Pharm Sci; 2016 May; 87():47-51. PubMed ID: 26493584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The Medical Product Agency's work and economics--a comment].
    Ahlqvist Rastad J; Salmonson T
    Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
    [No Abstract]   [Full Text] [Related]  

  • 29. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [National and European drug approval procedures].
    Mohrbutter KP
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):593-6. PubMed ID: 9527447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [How does a new medicine reach the patient?].
    Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
    Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The network of official medicines control laboratories].
    Buchheit KH; Wanko R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presentation and distribution of medicinal products after the new E.U. marketing procedures.
    Montanari L; Minghetti P; Giudici EM
    Pharmacol Res; 1997 Jan; 35(1):37-42. PubMed ID: 9149314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathways to faster access to medicines.
    Drug Ther Bull; 2018 Aug; 56(8):93-96. PubMed ID: 30135065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutual Recognition of the Food and Drug Administration and European Community Member State Conformity Assessment Procedures; pharmaceutical GMP inspection reports, medical device quality system evaluation reports, and certain medical device premarket evaluation reports--FDA. Proposed rule.
    Fed Regist; 1998 Apr; 63(69):17744-71. PubMed ID: 10177764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International regulatory aspects of clinical periodontal research.
    Cooley WE; Castellion AW
    Ann Periodontol; 1997 Mar; 2(1):18-30. PubMed ID: 9151540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe.
    Ebbers HC; Langedijk J; Bouvy JC; Hoekman J; Boon WP; de Jong JP; De Bruin ML
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1237-44. PubMed ID: 26204969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
    Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
    Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.